GH Research PLC

GH Research PLC (GHRS) priced its initial public offering on Jun 28, 2021 at $16.00 per share, within its $14.00–$16.00 range, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $808.3M. TD Cowen was lead-left underwriter, joined by Stifel, Canaccord Genuity and Citizens JMP. Davis Polk and Dentons advised the company and Cooley and Arthur Cox advised the underwriters.

GH Research PLC is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological disorders. It focuses on 5-MeO-DMT therapies for treatment-resistant depression, with GH001 as an inhalable candidate and GH002 as an injectable one.

Status

IPO

Ticker

GHRS

Exchange

Nasdaq Global Market

Priced

Jun 28, 2021

IPO price

$16.00

Price range

$14.00–$16.00

Market cap at IPO price

$808.3M

First filed

Jun 4, 2021

Underwriters

TD Cowen, Stifel, Canaccord Genuity and Citizens JMP

Company counsel

Davis Polk and Dentons

Underwriters' counsel

Cooley and Arthur Cox

Sector

Biotech & pharma

Country / state

Ireland

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.